Evidence map›Paper›PMID 35344749›Full record

ArticleESMO open2022

Androgen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic.

N Araújo, A Costa, L Lopes-Conceição, A Ferreira, F Carneiro, J Oliveira, I Braga, S Morais, L Pacheco-Figueiredo, L Ruano and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Risks associated with cognitive function and management strategies in the clinical use of ADT: a systematic review from clinical and preclinical studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Anxiety and Depression in Patients with Prostate Cancer, at Cancer Diagnosis and after a One-Year Follow-Up.International journal of environmental research and public health · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

N AraújoEPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal; Laboratório Para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal.
A CostaEPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal; Laboratório Para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal.
L Lopes-ConceiçãoEPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.
A FerreiraInstituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida, Porto, Portugal.
F CarneiroInstituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida, Porto, Portugal.
J OliveiraInstituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida, Porto, Portugal.
I BragaInstituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida, Porto, Portugal.
S MoraisEPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal; Laboratório Para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal. Electronic address: https://twitter.com/samanthafmorais.
L Pacheco-FigueiredoInstituto de Investigação em Ciências da Vida e Saúde, Escola de Medicina da Universidade do Minho, Campus de Gualtar, Braga, Portugal.
L RuanoEPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal; Laboratório Para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal. Electronic address: https://twitter.com/lmruano.
V T CruzEPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal; Laboratório Para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal.
S PereiraEPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal; Laboratório Para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal; Instituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida, Porto, Portugal.
N LunetEPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal; Laboratório Para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal; Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidade do Porto, Alameda Professor Hernâni Monteiro, Porto, Portugal. Electronic address: nlunet@med.up.pt.
Instituto de Saúde · BRIPO Porto · PTi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTUniversidade do Porto · PTUniversity of Minho · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAndrogen-deprivation therapy (ADT) has been associated with cognitive decline, but results are conflicting. This study describes changes in cognitive performance in patients with prostate cancer, according to ADT, during the first year after prostate cancer diagnosis. PATIENTS AND

methodsPatients with prostate cancer treated at the Portuguese Institute of Oncology of Porto (n = 366) were evaluated with the Montreal Cognitive Assessment (MoCA), before treatment and after 1 year. All baseline evaluations were performed before the coronavirus disease 2019 (COVID-19) pandemic and 69.7% of the 1-year assessments were completed after the first lockdown. Cognitive decline was defined as the decrease in MoCA from baseline to the 1-year evaluation below 1.5 standard deviations of the distribution of changes in the whole cohort. Participants scoring below age- and education-specific normative reference values in the MoCA were considered to have cognitive impairment. Age- and education-adjusted odds ratios (aORs) were computed for the association between ADT and cognitive outcomes.

resultsMean MoCA scores increased from baseline to the 1-year evaluation (22.3 versus 22.8, P < 0.001). Cognitive decline was more frequent in the ADT group, and even more after the onset of the COVID-19 pandemic (aOR 6.81 versus 1.93, P for interaction = 0.233). The 1-year cumulative incidence of cognitive impairment was 6.9% (9.1% before and 3.7% after the pandemic onset), which was higher among patients receiving ADT, but only after the pandemic (aOR 5.53 versus 0.49, P for interaction = 0.044).

conclusionsADT was associated with worse cognitive performance of patients with prostate cancer, mostly among those evaluated after the first COVID-19 lockdown.

Indexed as

Cognitive DysfunctionCOVID-19Prostatic NeoplasmsAndrogen AntagonistsAndrogensCommunicable Disease ControlHumansMaleNeonPandemicsProspective StudiesAndrogen AntagonistsAndrogensNeonCOVID-19, complicationshormone antagonists/analogues and derivativeshormoneshormone substituteslongitudinal studiesneurocognitive disordersprostate cancer

Identifiers

PMID35344749
PMCPMC8898674
OpenAlexW4220876994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.